Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Jul 22;41(8):488-494.
doi: 10.1136/emermed-2024-213904.

Clinical decision aids and computed tomography coronary angiography in patients with suspected acute coronary syndrome

Kang-Ling Wang  1   2   3 , Caelan Taggart  4   5 , Michael McDermott  4 , Rachel O'Brien  6 , Katherine Oatey  7 , Liza Keating  8 , Robert F Storey  9   10 , Dirk Felmeden  11 , Nick Curzen  12   13 , Attila Kardos  14 , Carl Roobottom  15 , Jason Smith  16 , Steve Goodacre  17 , David E Newby  4 , Alasdair J Gray  6   18 ; RAPID-CTCA Investigators
Collaborators, Affiliations
Free article
Randomized Controlled Trial

Clinical decision aids and computed tomography coronary angiography in patients with suspected acute coronary syndrome

Kang-Ling Wang et al. Emerg Med J. .
Free article

Abstract

Background: The HEART score, the T-MACS model and the GRACE score support early decision-making for acute chest pain, which could be complemented by CT coronary angiography (CTCA). However, their performance has not been directly compared.

Methods: In this secondary analysis of a multicentre randomised controlled trial of early CTCA in intermediate-risk patients with suspected acute coronary syndrome, C-statistics and performance metrics (using the predefined cut-offs) of clinical decision aids and CTCA, alone and then in combination, for the index hospital diagnosis of acute coronary syndrome and for 30-day coronary revascularisation were assessed in those who underwent CTCA and had complete data.

Results: Among 699 patients, 358 (51%) had an index hospital diagnosis of acute coronary syndrome, for which the C-statistic was higher for CTCA (0.80), followed by the T-MACS model (0.78), the HEART score (0.74) and the GRACE score (0.60). The negative predictive value was higher for the absence of coronary artery disease on CTCA (0.90) or a T-MACS estimate of <0.05 (0.83) than a HEART score of <4 (0.81) and a GRACE score of <109 (0.55). For 30-day coronary revascularisation, CTCA had the greatest C-statistic (0.80) with a negative predictive value of 0.96 and 0.92 in the absence of coronary artery disease and obstructive coronary artery disease, respectively. The combination of the T-MACS estimates and the CTCA findings was most discriminative for the index hospital diagnosis of acute coronary syndrome (C-statistic, 0.88) and predictive of 30-day coronary revascularisation (C-statistic, 0.85). No patients with a T-MACS estimate of <0.05 and normal coronary arteries had acute coronary syndrome during index hospitalisation or underwent coronary revascularisation within 30 days.

Conclusions: In intermediate-risk patients with suspected acute coronary syndrome, the T-MACS model combined with CTCA improved discrimination of the index hospital diagnosis of acute coronary syndrome and prediction of 30-day coronary revascularisation.

Trial registration number: NCT02284191.

Keywords: clinical.

PubMed Disclaimer

Conflict of interest statement

Competing interests: KO reports research grants from the British Heart Foundation, the Jon Moulton Charity Trust and University of Edinburgh. RFS reports research grants from AstraZeneca and Cytosorbents; consulting fees and/or honoraria from Alfasigma, AstraZeneca, Chiesi, Cytosorbents, Daiichi-Sankyo, Idorsia, Novartis, Novo Nordisk, Pfizer, PhaseBio and Tabuk. NC reports research grants from Beckman Coulter, Boston Scientific, HeartFlow and Haemonetics; consulting fees and/or honoraria from Abbott, Boston Scientific and Edwards Lifesciences; travel sponsorship from Abbott, Biosensors and Edwards Lifesciences. AK reports honoraria from the TomTec Imaging Systems. CR reports honoraria from GE HealthCare.

Publication types

Associated data